• Commercial excellence in pharma 3.0

    The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • Insights from 30 years of biotech IPOs

    In our latest blog post, Global Life Sciences Leader Glen Giovannetti shares his thoughts on past IPO cycles and the outlook for 2014.

  • Worldwide research and development incentive guide

    Research and development (R&D) incentives have grown in number and importance in recent years. Read our latest guide detailing R&D incentive regimes in 34 countries.

  • Firepower and Growth Gap Report 2014

    Big pharma needs mergers and acquisitions to grow, but the deal landscape is more competitive than ever. Read more about pharma's growth gap in our report.

  • Pulse of the industry - medical technology report 2013

    Facing regulatory pressures, resource constraints, and changing health care industry, the medtech industry must redefine innovation to deliver value for payers and patients. Read more.

  • Cash on prescription 2013

    The 14 leading pharma companies have up to US$40 billion tied up unnecessarily in working capital. What strategies can help companies increase efficiency?

  • Beyond Borders: global biotech report 2013

    We saw a strong performance by major biotech players, but a challenging environment for the rest of the industry. Read more in our 2013 industry report

  • Life Sciences deal sentiment scorecard

    What lies ahead in the deal space? Our scorecard is based on investor presentations, meetings and conversations around the 2013 J.P. Morgan Healthcare Conference.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:


  • Biotechnology

    More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.

    But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.

    We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.

    We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.

    So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.

    Take a closer look:

  • Pharmaceutical

    Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.

    We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.

    Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.

    Take a closer look:

  • Medical technology

    Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.

    Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.

    Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.

    From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.

    Take a closer look:



Contact us

EY-Adrian Browne

Adrian Browne
Partner
Head of Transaction Advisory Services
Email Adrian Browne
 +44 (0)20 7951 0465

 

EY-Aidan Meagher

Aidan Meagher
Irish Life Sciences Lead
Director, International Tax Services
 +353 (1) 221 1139
linkedIn Aidan Meagher Aidan Meagher

 

 

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

Download

EY – Big data can make your business flyReady for takeoff? Overcoming the challenges of big data

Full report
Executive summary



RHF graphic for life sciences blog

 EY Data Analytics

Data Analytics

Utilise the benefits of your data with predictive, prescriptive and forensic analytics.

Download

EY – Big data can make your business flyReady for takeoff? Overcoming the challenges of big data

Full report
Executive summary



EY-Applying IFRS 10 and IFRS 11

Applying IFRS 10 and IFRS 11

How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.

 

EY - Biopharma in an era of elusive growth

Biopharma in an era of elusive growth

Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.